Country, language and currency
- Social bookmarks:
- Testimonials
-
Read more »
- Articles
Our billing is certified by:
-
- Patients' Expectations About New HCV Direct-Acting Antivirals Often Unrealistic - Gastroenterology & Endoscopy News
- Gastroenterology & Endoscopy NewsPatients' Expectations About New HCV Direct-Acting Antivirals Often UnrealisticGastroenterology & Endoscopy Newsby Christina Frangou San Francisco—Soon after the FDA approved two direct-acting antiviral agents (DAAs) last spring for treating infection with hepatitis C virus (HCV), a 57-year-old black man came to see gastroenterologist Andrew Muir, MD
- Hepatitis C Study Drug Fails; Most Patients Relapse - Medscape
- Kapitall BlogHepatitis C Study Drug Fails; Most Patients RelapseMedscapeNull responders represent 'a challenging patient population to cure,' said Norbert Bischofberger, PhD, Gilead's chief scientific officer, noting that additional direct-acting antivirals or an extended duration of therapy may be needed to achieve better
- Patients relapse after Gilead hepatitis C treatment - PMLiVE
- Patients relapse after Gilead hepatitis C treatmentPMLiVEGS-7977 was one of the main assets behind Gilead's $10
- UK company, OnlineClinic, expands services for STI's, travel medicine - Examiner.com
- UK company, OnlineClinic, expands services for STI's, travel medicineExaminer
- Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide ... - MarketWatch (press release)
- CitybizlistIdenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide
